Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

• Published in: Journal of clinical oncology Vol. 29; no. 12; pp. 1634 - 1642
• Main Authors: Hehlmann, Rüdiger, Lauseker, Michael, Jung-Munkwitz, Susanne, Leitner, Armin, Müller, Martin C., Pletsch, Nadine, Proetel, Ulrike, Haferlach, Claudia, Schlegelberger, Brigitte, Balleisen, Leopold, Hänel, Mathias, Pfirrmann, Markus, Krause, Stefan W., Nerl, Christoph, Pralle, Hans, Gratwohl, Alois, Hossfeld, Dieter K., Hasford, Joerg, Hochhaus, Andreas, Saußele, Susanne
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Society of Clinical Oncology 20.04.2011
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Benzamides; Biological and medical sciences; Chi-Square Distribution; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Germany; Hematologic and hematopoietic diseases; Humans; Imatinib Mesylate; Interferon-alpha - administration & dosage; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; Piperazines - administration & dosage; Protein Kinase Inhibitors - administration & dosage; Pyrimidines - administration & dosage; Remission Induction; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome; Tumors; Young Adult; Germany; Antineoplastic agent; Imatinib; Enzyme; Tyrosine kinase inhibitor; Alpha interferon; Transferases; Enzyme inhibitor; Chronic myelogenous leukemia; Early stage; Malignant hemopathy; Myeloproliferative syndrome; Cancerology; Protein-tyrosine kinase; Comparative study; Cancer

Treatment of chronic-phase (CP) chronic myeloid leukemia (CML) with imatinib 400 mg/d can be unsatisfactory. Optimization of treatment is warranted. In all, 1,014 newly diagnosed CP-CML patients were randomly assigned to imatinib 800 mg/d (n = 338), imatinib 400 mg/d (n = 325), or imatinib 400 mg/d...